Emerald Advisers LLC Has $29.32 Million Position in LivaNova PLC (NASDAQ:LIVN)

Emerald Advisers LLC reduced its position in LivaNova PLC (NASDAQ:LIVN - Free Report) by 0.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 746,513 shares of the company's stock after selling 6,027 shares during the quarter. LivaNova comprises about 1.3% of Emerald Advisers LLC's portfolio, making the stock its 26th largest position. Emerald Advisers LLC owned about 1.37% of LivaNova worth $29,323,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of LIVN. UMB Bank n.a. lifted its holdings in shares of LivaNova by 340.5% in the first quarter. UMB Bank n.a. now owns 837 shares of the company's stock worth $33,000 after acquiring an additional 647 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of LivaNova by 17.1% in the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock worth $70,000 after acquiring an additional 219 shares during the last quarter. Sterling Capital Management LLC lifted its holdings in shares of LivaNova by 800.6% in the fourth quarter. Sterling Capital Management LLC now owns 1,621 shares of the company's stock worth $75,000 after acquiring an additional 1,441 shares during the last quarter. Central Pacific Bank Trust Division lifted its holdings in shares of LivaNova by 7.0% in the first quarter. Central Pacific Bank Trust Division now owns 4,407 shares of the company's stock worth $173,000 after acquiring an additional 290 shares during the last quarter. Finally, Vestcor Inc bought a new position in shares of LivaNova in the fourth quarter worth about $204,000. 97.64% of the stock is owned by institutional investors.

Analyst Ratings Changes

LIVN has been the subject of a number of research reports. Needham & Company LLC reiterated a "buy" rating and issued a $64.00 price objective on shares of LivaNova in a report on Tuesday, May 13th. Barclays dropped their price objective on shares of LivaNova from $56.00 to $55.00 and set an "equal weight" rating for the company in a report on Thursday, May 8th. Wolfe Research raised shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 target price for the company in a research report on Tuesday, May 20th. Wall Street Zen downgraded shares of LivaNova from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 8th. Finally, Robert W. Baird increased their target price on shares of LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $59.29.

LivaNova Trading Down 1.0%

NASDAQ:LIVN traded down $0.44 on Wednesday, reaching $42.99. 540,319 shares of the stock traded hands, compared to its average volume of 627,738. The firm has a market capitalization of $2.34 billion, a price-to-earnings ratio of -10.51 and a beta of 0.90. LivaNova PLC has a 1-year low of $32.48 and a 1-year high of $57.35. The company has a current ratio of 1.58, a quick ratio of 1.37 and a debt-to-equity ratio of 0.53. The company's 50 day moving average is $44.85 and its 200-day moving average is $43.23.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.